Torrent Pharmaceuticals has announced a board meeting to approve the financial results for the quarter and half-year. The company has communicated the availability of its 52nd Annual General Meeting notice and Integrated Annual Report for FY 2024-25 via electronic mode to shareholders. Investors are encouraged to update their email addresses with the Registrar or Depository Participants for seamless access to company communications. No operational changes or new business developments were disclosed in this update.